From L-R: Scarlet scientific founders Ash Toye and Jan Frayne, and CEO Alistair Irvine

May 23, 2023 07:35 AM EDTUpdated 10:56 AM

In wake of Rubius downfall, a new biotech spinout launches to 'take the next step' in red blood cell therapies

Amber Tong

When Alistair Irvine first started raising money for a University of Bristol spinout named Scarlet Therapeutics about two years ago, he got one question a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

In wake of Rubius downfall, a new biotech spinout launches to 'take the next step' in red blood cell therapies

Amber Tong

Sign up to read this article for free.

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

Bristol Myers' schizophrenia drug fails Phase 3 trial for adjunctive treatment

Ascletis posts puzzling Phase 1 update on obesity pill

China’s biotech market is staging a comeback that US biotech can only wish for

Genentech vet launches ADC startup with $20M

With aims to become a 'generational biotech,' Zealand Pharma hires Lilly veteran as science chief

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

In wake of Ru­bius down­fall, a new biotech spin­out launch­es to 'take the next step' in red blood cell ther­a­pies

Sign up to read this article for free.

Gondolabio

Palo Alto, CA, USA

In wake of Rubius downfall, a new biotech spinout launches to 'take the next step' in red blood cell therapies